Preparation method of litamilast and intermediate compound of litamilast

A novel synthesis method for lifalast using alkaline hydrolysis and solvent extraction addresses high costs and impurity issues, achieving high purity and cost-effective industrial production.

CN119060022AActive Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411208185.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2021-09-18
Publication Date
2024-12-03
Estimated Expiration
2041-09-18

AI Technical Summary

Technical Problem

Existing methods for synthesizing lifitegrast, such as hydrolysis or hydrogenation, result in high production costs and impurity formation, particularly due to racemization under strong alkaline conditions, making purification challenging and costly.

Method used

A method involving hydrolysis of compound formula I or its solvate under alkaline conditions using inorganic and organic bases, followed by solvent extraction and pH adjustment, to produce lifalast with high purity and minimal impurities, utilizing a new crystalline form of compound formula III to inhibit impurity formation.

Benefits of technology

The method achieves lifalast purity greater than 99.9% with less than 0.1% impurity, significantly reducing production costs and simplifying the process, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005019624720000011
    Figure BDA0005019624720000011
  • Figure BDA0005019624720000012
    Figure BDA0005019624720000012
  • Figure BDA0005019624720000021
    Figure BDA0005019624720000021
Patent Text Reader

Abstract

The invention relates to a preparation method of litamilast and an intermediate compound of the litamilast. Specifically, the invention relates to a synthesis method of the litamilast, a key intermediate for synthesizing the litamilast, a solvate of the litamilast and a method for preparing the litamilast by hydrolyzing the litamilast under an alkaline condition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with application number 202111110390.4 filed on September 18, 2021 and invention name “Method for preparing lifastat and its intermediate compounds”. Technical Field

[0002] The present invention relates to the field of organic compound synthesis, and in particular to a synthesis method of lisdenafil, a key intermediate for synthesizing lisdenafil, and a preparation method thereof. Background Art

[0003] Lifitegrast was developed by Shire Pharmaceuticals. It is a new type of small molecule integrin inhibitor that can antagonize lymphocyte-associated antigens, block their interaction with their cognate ligands and intercellular adhesion molecules, and interfere with the overexpression of corneal and conjunctival tissues that causes dry eye disease. It was approved by the U.S. Food and Drug Administration (FDA) for sale in the United States on July 11, 2016.

[0004]

[0005] Common preparation methods of lifalast include hydrolysis or hydrogenation of the ester group of its precursor. As shown in Scheme 1, WO2009139817A2, WO2011050175A1 and WO2019096996A1 disclose that the compound of formula II is hydrogenated under the catalysis of precious metal palladium carbon to obtain lifalast, but this route has precious metal residues and the production cost is relatively high.

[0006]

[0007] As shown in Scheme 2, WO2019097547A1 utilizes alkaline hydrolysis of the compound of formula III to obtain lifalast. Although the process seems simple, in actual production, the chiral configuration of the chiral amino acid derivative is easily racemized under strong alkaline conditions to produce impurity A, which is very unfavorable for the purification of lifalast.

[0008]

[0009] In view of the shortcomings of the existing methods, the inventors unexpectedly discovered a method suitable for the industrial production of lifalast in their research, which can not only effectively inhibit the formation of impurity A, but also is simple to operate and can significantly reduce production costs. In addition, the inventors also obtained a new solvate crystalline form of the compound of formula III. When lifalast is prepared using the crystalline form, the product purity can be greater than 99.9%, and the single impurity is less than 0.1%, or even equal to zero. In addition, the preparation method of the crystalline form is simple, so it can reduce costs, thereby solving the defects in the existing methods. Summary of the invention

[0010] In this application, the following terms have the meanings set out below:

[0011] "DMF" means N,N-dimethylformamide.

[0012] "DMA" means N,N-dimethylformamide.

[0013] "NMP" means N-methylpyrrolidone.

[0014] "DMSO" means dimethyl sulfoxide.

[0015] "DIPEA" means N,N-diisopropylethylamine.

[0016] "THF" means tetrahydrofuran.

[0017] The term "alkyl" refers to a straight or branched saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms. Preferably, the alkyl group has 1-10, such as 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 carbon atoms. 1-10 Alkyl" and "C 1-6 The term "alkyl" refers to a straight or branched saturated hydrocarbon group having 1 to 10 and 1 to 6 carbon atoms, respectively. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,3-dimethylbutyl, 3-methylpentyl, cyclohexyl, n-heptyl or n-octyl.

[0018] The term "alkoxy" refers to the group R'-O-, wherein R' is an alkyl group as defined above. 1-6 "Alkoxy" means a group R'-O-, wherein R' is C as defined above 1-6 alkyl.

[0019] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0020] The term "haloalkyl" refers to an alkyl group as described above, wherein one or more (e.g., 1, 2, 3, 4 or 5) hydrogen atoms are replaced by halogen, wherein the halogen is selected from fluorine, chlorine, bromine and iodine. Preferably, the haloalkyl group is "C 1-10 "Haloalkyl" or "C 1-6 -haloalkyl". Examples include, for example, -CH2F, -CHF2, -CF3, -CCl3, -C2F5, -C2Cl5, -CH2CF3, -CH2Cl, -CH2CH2CF3 or -CF(CF3)2.

[0021] The term "haloalkoxy" refers to an alkoxy group as described above, wherein one or more (e.g., 1, 2, 3, 4 or 5) hydrogen atoms are replaced by halogen, wherein the halogen is selected from fluorine, chlorine, bromine and iodine. Preferably, the haloalkyl group is "C 1-10 Haloalkoxy" or "C 1-6 The term "haloalkoxy" refers to a "haloalkoxy" group. Examples thereof include, for example, -O-CH2F, -O-CHF2, -O-CF3, -O-CH2CF3, -O-CH2Cl, or -O-CH2CH2CF3.

[0022] The term "cycloalkyl" refers to a monocyclic, fused polycyclic, bridged polycyclic or spirocyclic non-aromatic saturated monovalent hydrocarbon ring structure having a specified number of ring atoms. A cycloalkyl group may have 3 to 12 carbon atoms (i.e., C3-C 12 Cycloalkyl) such as 3 to 10, 3 to 8, 3 to 7, 3 to 6, or 5 to 6 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

[0023] The term "aryl" refers to a monovalent aromatic hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom in an aromatic ring system. Specifically, aryl refers to a monocyclic or fused polycyclic aromatic ring structure having a specified number of ring atoms. For example, aryl includes groups containing 6 to 14, such as 6 to 10, preferably 6 ring atoms. Examples of aryl groups include C 6-14 Aryl or C 6-10 Aryl, for example phenyl or naphthyl, preferably phenyl.

[0024] The term "aralkyl" refers to an alkyl group as described above substituted with an aryl group as described above, for example, C6-C 10 Aryl-C 1-6 Alkyl, for example benzyl.

[0025] The term "optionally substituted" means that the group may be unsubstituted or substituted with one or more (eg, 1, 2, 3, 4 or 5 or more) substituents, wherein the substituents may be the same or different.

[0026] "Optionally substituted cycloalkyl" means optionally substituted with one, two or three identical or different cycloalkyl groups selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogen, C 1-6 Haloalkyl and C 1-6 Cycloalkyl substituted by haloalkoxy substituents, such as C 3-8 Cycloalkyl, for example C substituted with one, two or three substituents selected from halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy 3-8 Cycloalkyl.

[0027] "Optionally substituted aryl" means optionally substituted with one, two or three identical or different aryl groups selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogen, C 1-6 Haloalkyl and C 1-6 Aryl substituted with a haloalkoxy substituent, such as C6-C 10 Aryl, such as phenyl, for example phenyl substituted with one, two or three substituents selected from halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy.

[0028] The term "optionally substituted aralkyl" refers to an alkyl radical which is optionally substituted with one, two or three identical or different alkyl radicals selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogen, C 1-6 Haloalkyl and C 1-6 Aralkyl substituted with a haloalkoxy substituent, such as C6-C 10 Aryl-C 1-6 Alkyl, such as benzyl, for example benzyl substituted with one, two or three substituents selected from halogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethoxy.

[0029] In a first aspect, the present invention provides a method for preparing lifalast, the method comprising:

[0030] The compound of formula I or its salt or solvate is hydrolyzed under alkaline conditions to obtain ritamilast,

[0031]

[0032] wherein R is selected from alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted aralkyl, preferably C 1-10 Alkyl, C 6-10 Aryl, or C 6-10 Aryl-C 1-10 Alkyl groups, such as C 1-6 Alkyl or C 6-10 Aryl-C 1-6 alkyl, particularly preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or benzyl, and

[0033] The alkaline condition is to carry out hydrolysis in the presence of an inorganic base and an organic base.

[0034] In a preferred embodiment, the inorganic base is selected from alkali metal or alkaline earth metal hydroxide, carbonate, bicarbonate, hydride or any combination thereof, such as any one of lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, Ba(OH)2, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride and calcium hydride, or a combination of any two or more thereof.

[0035] In a preferred embodiment, the organic base is selected from alkoxides, organic amines or any combination thereof, such as sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, ethylamine, n-propylamine, isopropylamine, n-butylamine, ethylenediamine, dimethylethylenediamine, trimethylethylenediamine, tetramethylethylenediamine, trimethylamine, triethylamine, triethanolamine, DIPEA, pyridine, 4-dimethylaminopyridine, imidazole, methylimidazole, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, piperazine, N-methylpiperazine, tetrabutylammonium hydroxide, N,N-dimethylaniline, N,N-dimethylcyclohexylamine, hexamethylphosphoric triamide, any one or a combination of any two or more thereof.

[0036] The salt of the compound of formula I is selected from salts formed with organic acids or inorganic acids, preferably pharmaceutically acceptable salts, such as hydrochloride, sulfate, phosphate, nitrate, acetate or benzoate.

[0037] In a preferred embodiment, the solvate of the compound of formula I is selected from the solvate formed by the compound of formula I or its salt and an organic solvent such as methanol, ethanol, isopropanol, ether, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether, toluene, acetonitrile, acetone or butanone, preferably the solvate described in the second aspect below.

[0038] In a more preferred embodiment, the method comprises one or more of the following steps:

[0039] (1) adding the compound of formula I or its salt or solvate into a reaction solvent and stirring to dissolve;

[0040] (2) adding an inorganic base and an organic base into purified water, stirring to dissolve, controlling the reaction temperature to -10 to 60° C., adding the solution prepared in step (1) dropwise to the aqueous solution of the base, and stirring until the reaction is complete;

[0041] (3) The reaction mixture is concentrated under reduced pressure to remove the reaction solvent, extracted with an organic solvent, and an acid is added to adjust the pH to 1-4 to precipitate a solid to obtain lifalast.

[0042] In a specific embodiment, after the solid is precipitated in step (3), it is filtered, washed with water, and dried at 20-70° C. to obtain the lifalast product with a yield of ≥94.5%, a purity of ≥99.8%, an ee value of ≥99.8%, and a single impurity of ≤0.1%.

[0043] In step (1), the reaction solvent is selected from water, an organic solvent or a mixture thereof, for example, any one of methanol, ethanol, n-propanol, isopropanol, THF, methyltetrahydrofuran, ether, isopropyl ether, methyl tert-butyl ether, 1,4-dioxane, ethyl acetate, isopropyl acetate, isopropyl formate, toluene, xylene, acetonitrile, DMF, DMA, NMP, DMSO, acetone, butanone, n-hexane, cyclohexane, n-heptane and purified water, or a combination of any two or more thereof.

[0044] In step (2), the inorganic base and the organic base are as described above.

[0045] In step (3), the organic solvent for extraction is selected from aprotic organic solvents, such as toluene, methyl formate, ethyl formate, isopropyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-hexane, cyclohexane, n-heptane, ether, isopropyl ether, methyl tert-butyl ether, dichloromethane and chloroform, any one or a combination of any two or more thereof.

[0046] In step (3), the acid is selected from an organic acid or an inorganic acid, such as any one of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, and benzoic acid, or a combination of any two or more thereof.

[0047] In step (1), the salt of the compound of formula I is selected from the salt formed with an organic acid or an inorganic acid, preferably a pharmaceutically acceptable salt, such as hydrochloride, sulfate, phosphate, nitrate, acetate or benzoate. The solvate is selected from the solvate formed by the compound of formula I or its salt and an organic solvent such as methanol, ethanol, isopropanol, ether, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether, toluene, acetonitrile, acetone, butanone. In a preferred embodiment, the solvate of the compound of formula I is the solvate described in the second aspect below.

[0048] In a second aspect, the present invention provides a solvate of the compound represented by formula IV.

[0049]

[0050] In a preferred embodiment, the compound of formula IV is in crystalline form, characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks expressed in 2θ diffraction angles at 6.12±0.2°, 20.12±0.2° and 20.94±0.2.

[0051] In a more preferred embodiment, the compound of formula IV is in crystalline form, characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at 6.12±0.2°, 17.40±0.2°, 17.70±0.2°, 20.12±0.2°, 20.94±0.2° and 22.5±0.2° expressed as 2θ diffraction angles.

[0052] In a more preferred embodiment, the compound of formula IV is in crystalline form, characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at 6.12±0.2°, 17.40±0.2°, 17.70±0.2°, 20.12±0.2°, 20.94±0.2°, 22.5±0.2°, 22.78±0.2°, 26.14±0.2°, 26.74±0.2° and 26.98±0.2°, expressed as 2θ diffraction angles.

[0053] In a more preferred embodiment, the compound of formula IV is in crystalline form characterized by having Figure 1 The X-ray powder diffraction pattern is shown.

[0054] The crystalline form of the compound of formula IV, when using Cu-Kα Radiation, tube voltage 40KV, tube current 250mA, scanning speed 5° / min, step width 0.02°, scanning range 3-50° (2θ) θ-2θ continuous scanning, with Figure 1 The X-ray powder diffraction pattern is shown in Table 1. The main characteristic diffraction lines represented by the 2θ diffraction angle are shown in Table 1.

[0055] Table 1: Main characteristic diffraction lines of compound IV

[0056]

[0057] The single crystal structure data of the compound of formula IV of the present invention are shown in Table 2, the atomic coordinates and isotropic temperature factor of the compound of formula IV are shown in Table 3, and the three-dimensional structure diagram of the compound of formula IV (the solvent molecules are ignored) is shown in Table 4. Figure 2 As shown, the layered stacking diagram (along the ac direction) of the compound of formula IV is as follows Figure 3 shown.

[0058] The above results show that the crystal of the compound of formula IV belongs to the monoclinic system, C2(5#) space group, and the unit cell parameters are: β=97.039(2)°, Z=4,Molecular formula:C 30 H 26Cl2N2O7S0.5(C4H8O), crystal density d = 1.403g / cm 3 Its smallest asymmetric unit contains a molecule of compound IV (structural formula: Figure 3 As shown in FIG. 1 , there is no hydrogen bonding between the tetrahydrofuran molecule and the compound of formula IV. The compound of formula IV molecules are connected to form a molecular dimer by intermolecular hydrogen bonding NH…O. The intermolecular weak interaction connects the molecular dimer into a layered stacking structure, and the THF molecule is located in the middle of the molecular layer of the compound of formula IV.

[0059] Table 2 Single crystal structure data and structure correction data of compound IV

[0060]

[0061]

[0062] Table 3 Atomic coordinates and isotropic temperature factors of the compound of formula IV

[0063]

[0064]

[0065] The DSC curve of the crystal of the compound of formula IV of the present invention is as follows: Figure 4 As shown, its melting point is 146.5°C.

[0066] The DSC-TGA curve of the crystal of the compound of formula IV of the present invention is as follows: Figure 5 As shown, it shows that its structure contains about 5.3% solvent. This is consistent with the results of single crystal diffraction analysis. From the single crystal diffraction results, it can be seen that the cross-linked intermediate of the compound of formula IV is a THF solvate, that is, the structure contains half a tetrahydrofuran molecule, and the molecular formula is: C 30 H 26 C l2 N2O7S·0.5(C4H8O), molecular weight is 665.57. The weight ratio of half tetrahydrofuran is: 36.06 / 665.57*100%=5.4% (the molecular weight of tetrahydrofuran is 72.11, half tetrahydrofuran is 36.06).

[0067] In a third aspect, the present invention provides a method for preparing a solvate of formula IV, the method comprising:

[0068] (a) adding a crude compound of formula III to a crystallization solvent, dissolving it, cooling it, and crystallizing it to obtain a crystalline compound of formula IV,

[0069]

[0070] In a specific embodiment, step (a) is to add the crude product of formula III to a crystallization solvent, heat to dissolve, then cool to crystallize, filter and dry to obtain a compound of formula IV in crystalline form.

[0071] The crystallization solvent is selected from tetrahydrofuran, or a mixture of tetrahydrofuran and any one or two or more solvents selected from methanol, ethanol, propanol, isopropanol, toluene, xylene, chlorobenzene, acetonitrile, 2-methyltetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, ethyl acetate, isopropyl ether, methyl tert-butyl ether, hexane, n-hexane, cyclohexane, and n-heptane.

[0072] In a specific embodiment, the dissolution temperature is 20-100°C.

[0073] In a specific embodiment, the cooling and crystallization process is a programmed cooling and crystallization process, for example, cooling at a rate of 5-15° C. per hour.

[0074] In a specific embodiment, when the temperature drops to -10 to 25°C, the crystallization is carried out for 0.5-10 hours, and then a white wet product is obtained by filtration. The white wet product is dried at a drying temperature of 10-70°C to obtain a crystalline compound of formula IV.

[0075] In a fourth aspect, the present invention provides a method for preparing lifalast, which comprises hydrolyzing a solvate of formula IV under alkaline conditions to obtain lifalast,

[0076]

[0077] The alkaline condition is to carry out hydrolysis in the presence of an inorganic base and an organic base.

[0078] In a preferred embodiment, the inorganic base is selected from alkali metal or alkaline earth metal hydroxides, carbonates, bicarbonates, hydrides or any combination thereof, such as any one of lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride and calcium hydride, or a combination of any two or more thereof.

[0079] In a preferred embodiment, the organic base is selected from alkoxides, organic amines or any combination thereof, such as sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, ethylamine, n-propylamine, isopropylamine, n-butylamine, ethylenediamine, dimethylethylenediamine, trimethylethylenediamine, tetramethylethylenediamine, trimethylamine, triethylamine, triethanolamine, DIPEA, pyridine, 4-dimethylaminopyridine, imidazole, methylimidazole, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, piperazine, N-methylpiperazine, tetrabutylammonium hydroxide, N,N-dimethylaniline, N,N-dimethylcyclohexylamine, hexamethylphosphoric triamide, any one or a combination of any two or more thereof.

[0080] In a more preferred embodiment, the method comprises one or more of the following steps:

[0081] (1') adding the solvate crystals of formula IV into the reaction solvent and stirring to dissolve;

[0082] (2') adding an inorganic base and an organic base into purified water, stirring to dissolve, controlling the reaction temperature to -10 to 60°C, adding the solution prepared in step (1') dropwise to the aqueous solution of the base, and stirring until the reaction is complete;

[0083] (3') The reaction mixture was concentrated under reduced pressure to remove the reaction solvent, extracted with an organic solvent, and an acid was added to adjust the pH to 1-4 to precipitate a solid to obtain lifalast.

[0084] In a preferred embodiment, after the solid precipitates in step (3'), it is filtered, washed with water, and dried at 20-70°C to obtain lifalast with a yield of ≥97.2%, a purity of ≥99.8%, an ee value of ≥99.8%, and a single impurity of ≤0.1%.

[0085] In a preferred embodiment, the reaction solvent is as described above in the first aspect.

[0086] In a preferred embodiment, the inorganic base and the organic base in step (2') are as described above in the first aspect.

[0087] In a preferred embodiment, the extraction solvent is as described above in the first aspect.

[0088] In another embodiment, the method further comprises step (a) of the third aspect above.

[0089] In a preferred embodiment, the method comprises:

[0090] (a) adding a crude compound of formula III to a crystallization solvent, dissolving it, cooling it, and crystallizing it to obtain a solvate of formula IV in crystalline form; and

[0091] (b) dissolving the solvate crystals of formula IV in a reaction solvent and hydrolyzing them under alkaline conditions to obtain lifalast,

[0092]

[0093] The alkaline condition is to carry out hydrolysis in the presence of an inorganic base and an organic base.

[0094] In a preferred embodiment, step (a) is as described above in the third aspect.

[0095] In a preferred embodiment, the reaction solvent in step (b) is selected from water, an organic solvent or a mixture thereof, such as any one or a combination of any two or more of methanol, ethanol, n-propanol, isopropanol, THF, methyltetrahydrofuran, ether, isopropyl ether, methyl tert-butyl ether, 1,4-dioxane, ethyl acetate, isopropyl acetate, isopropyl formate, toluene, xylene, acetonitrile, DMF, DMA, NMP, DMSO, acetone, butanone, n-hexane, cyclohexane, n-heptane and purified water.

[0096] In a more preferred embodiment, the step (b) comprises the above-mentioned steps (1'), (2') and (3').

[0097] The conditions for steps (1'), (2'), and (3') are the same as those described for steps (1), (2), and (3) in the corresponding embodiments of the first to third aspects above, respectively.

[0098] The present invention unexpectedly discovered a method for preparing lisdaplast by hydrolyzing a compound of formula I or formula IV in the presence of an organic base and an inorganic base. Surprisingly, the method has the advantages of high product purity, good ee value of the obtained product and very few impurities, overcoming the problems of low purity and low ee value in the prior art, especially when lisdaplast is prepared using a solvate of formula IV, the product purity can be greater than 99.9%, and a single impurity is less than 0.1% or even zero. Moreover, the method has a simple process, is very suitable for industrial production, and can significantly reduce costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] Figure 1 It is the XRPD pattern of the crystal of compound of formula IV.

[0100] Figure 2 Figure 3 is the three-dimensional structure diagram of the crystal of compound IV (solvent molecules are ignored).

[0101] Figure 3 It is a layer stacking diagram of the crystal of the compound of formula IV (along the ac direction).

[0102] Figure 4 It is the DSC curve of the crystal of compound of formula IV.

[0103] Figure 5 It is the DSC-TGA curve of the crystal of compound of formula IV. DETAILED DESCRIPTION

[0104] The method of the present invention is further described by the following examples. It should be understood that the purpose of providing the following examples is only to enable a better understanding of the present invention, and is not intended to limit the scope of the present invention in any way.

[0105] Example 1: Preparation of the compound of formula III

[0106]

[0107] Method 1:

[0108] Dissolve 46g of compound VI, 14.5g of compound V and 34.2g of HATU in 460g of DMF and cool to -5 to 5°C. Add 9.6g of triethylamine dropwise and keep warm for 4-6 hours to react. After the reaction is completed, add the reaction solution dropwise to 500g of ice water to quench and filter. Dissolve the filter cake in 300g of dichloromethane and wash with water. Collect the organic layer and concentrate to dryness to obtain 55.5g of crude compound of formula III with a yield of 100% and a purity of 95.6%.

[0109] Method 2:

[0110] 14.2 g of compound V and 0.1 g of DMF were dissolved in 45 g of dichloromethane, the temperature was raised to reflux, 10.8 g of thionyl chloride was added dropwise, and after the reaction was completed, the mixture was concentrated to dryness, 30 g of dichloromethane was added to dissolve, and then the mixture was added dropwise to a pre-prepared 400 g dichloromethane solution containing 45 g of compound VI. After the reaction was completed, 100 g of the mixture was washed twice with water, the liquids were separated, and the organic phase was concentrated to dryness to obtain 54.3 g of a crude product of compound III with a yield of 100% and a purity of 95.5%.

[0111] Example 2: Preparation of Compound of Formula IV

[0112]

[0113] Method 1:

[0114] Weigh 20g of the crude compound of formula III into a round-bottom flask, add 30g of tetrahydrofuran, heat and reflux to dissolve, then add 10g of methyl tert-butyl ether, keep warm for 20-30 minutes, cool naturally to crystallize, continue stirring for 1.0-1.5h at 5-10°C, filter to obtain a white crystalline powder solid. Dry at 45-55°C to obtain 18.9g, with a yield of 94.5%, a purity of 99.7%, and a maximum single impurity of less than 0.1%.

[0115] Method 2:

[0116] Weigh 30g of the crude compound of formula III and place it in a reaction bottle, add 30g of tetrahydrofuran and 30g of isopropyl ether, heat and stir to dissolve, continue stirring for 10 to 20 minutes, program cooling and crystallization, cool down 5-10°C per hour, keep warm at 30-40°C for crystallization for 1 hour. Then continue cooling and stirring to crystallize, continue stirring and crystallizing at 0-5°C for 1.0-1.5h, filter, and dry at 45-50°C to obtain 28.5g of white crystalline powder solid, with a yield of 95.0%, a purity of 99.7%, and a maximum single impurity of less than 0.1%.

[0117] Method 3:

[0118] Weigh 30g of the crude compound of formula III and place it in a reaction bottle, add 35g of tetrahydrofuran and 15g of n-heptane, stir, heat and reflux until completely dissolved, continue stirring for 10 to 20 minutes, program cooling and crystallization, and cool by 5-15°C per hour. After cooling to 0-10°C, continue stirring and crystallization for 1.0 to 1.5 hours, filter, wash with n-heptane, and dry at 45-55°C to obtain 28.6g of white crystalline powder solid, with a yield of 95.3%, a purity of 99.8%, and a maximum single impurity of less than 0.1%.

[0119] Example 3: Preparation of Litamilast from a compound of formula II (i.e., a compound of formula I in which R = Bn)

[0120]

[0121] Method 1 (inorganic base):

[0122] Add 70.6 g of the compound of formula II to 600 g of acetonitrile, stir to dissolve, and set aside. Add 11.2 g of potassium hydroxide to 1000 g of purified water, stir to dissolve. Control the reaction temperature from -10 to 30°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrated solution with 2×200 g of isopropyl acetate, add hydrochloric acid to adjust the pH to 1-4, precipitate the solid, filter, wash with 1000 g of water, and dry at 50-60°C to obtain 55.6 g of ritaminast, with a yield of 90.4%, a purity of 95.8%, an ee value of 95.6%, and an impurity A of 4.4%.

[0123] Method 2 (inorganic base + organic base):

[0124] Add 70.6 g of the compound of formula II to 600 g of acetonitrile, stir to dissolve, and set aside. Add 11.2 g of potassium hydroxide and 15.0 g of triethylamine to 1000 g of purified water, stir to dissolve. Control the reaction temperature from -10 to 30°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrated solution with 2×200 g of isopropyl acetate, add hydrochloric acid to adjust the pH to 1-4, precipitate the solid, filter, wash with 1000 g of water, and dry at 50-60°C to obtain 58.3 g of ritaminast, with a yield of 94.8%, a purity of 99.8%, an ee value of 99.8%, and impurity A of 0.02%.

[0125] Example 4: Preparation of Litamilast from a compound of formula III (i.e., a compound of formula I in which R = Me)

[0126]

[0127] Method 1 (inorganic base):

[0128] Add 63.0 g of compound III to 600 g of acetone, stir to dissolve, and set aside. Add 10.0 g of sodium hydroxide to 1000 g of purified water, stir to dissolve. Control the reaction temperature from -5 to 25°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrate with 2×150 g of ethyl acetate, add hydrochloric acid to adjust pH=1-4, precipitate solid, filter, wash with 1000 g of water, and dry at 55-65°C to obtain 56.4 g of ritaminast, with a yield of 91.7%, a purity of 96.2%, an ee value of 94.8%, and impurity A of 5.2%.

[0129] Method 2 (inorganic base + organic base):

[0130] Add 63.0 g of compound III to 600 g of acetone, stir to dissolve, and set aside. Add 10.0 g of sodium hydroxide and 19.4 g of DIPEA to 1000 g of purified water, stir to dissolve. Control the reaction temperature from -5 to 25°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrate with 2×150 g of ethyl acetate, add hydrochloric acid to adjust the pH to 1-4, precipitate the solid, filter, wash with 1000 g of water, and dry at 55-65°C to obtain 58.6 g of ritaminast, with a yield of 95.3%, a purity of 99.8%, an ee value of 99.9%, and impurity A of 0.01%.

[0131] Example 5: Preparation of Litamilast from the compound of formula IV

[0132]

[0133] Method 1 (inorganic base):

[0134] Add 66.6 g of compound IV to 800 g of tetrahydrofuran, stir to dissolve, and set aside. Add 10.0 g of sodium hydroxide to 1000 g of purified water, stir to dissolve. Control the reaction temperature to -5 to 20°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrated solution with 2×190 g of toluene, add hydrochloric acid to adjust the pH to 1-4, precipitate the solid, filter, wash with 1100 g of water, and dry at 50-70°C to obtain 56.8 g of ritaminast, with a yield of 92.4%, a purity of 96.5%, an ee value of 96.7%, and an impurity A of 3.3%.

[0135] Method 2 (inorganic base + organic base):

[0136] Add 66.6 g of compound IV to 800 g of tetrahydrofuran, stir to dissolve, and set aside. Add 10.0 g of sodium hydroxide and 15.5 g of N-methylpiperidine to 1000 g of purified water, stir to dissolve. Control the reaction temperature to -5 to 20°C, drop the above-prepared reaction solution into the sodium hydroxide aqueous solution, and stir until the reaction is complete. Concentrate under reduced pressure to remove the reaction solvent, extract the concentrated solution with 2×190 g of toluene, add hydrochloric acid to adjust the pH to 1-4, precipitate the solid, filter, wash with 1100 g of water, and dry at 50-70°C to obtain 59.8 g of ritaminast, with a yield of 97.2%, a purity of 99.9%, an ee value of 100%, and impurity A of 0%.

Claims

1. Compounds shown in Formula IV 2. The compound according to claim 1, wherein the compound of formula IV is in crystalline form, characterized in that The X-ray powder diffraction spectrum thereof has characteristic diffraction peaks expressed by 2θ diffraction angles at 6.12±0.2°, 20.12±0.2° and 20.94±0.

2.

3. The compound according to claim 1, wherein the compound of formula IV is in crystalline form, characterized in that Its X-ray powder diffraction pattern has characteristic diffraction peaks at 6.12±0.2°, 17.40±0.2°, 17.70±0.2°, 20.12±0.2°, 20.94±0.2° and 22.5±0.2° expressed by 2θ diffraction angles.

4. A method for preparing a compound of formula IV according to claim 1, the method comprising: (a) adding a crude compound of formula III to a crystallization solvent, dissolving it, cooling it, and crystallizing it to obtain a crystalline compound of formula IV, 5. The method according to claim 4, wherein the crystallization solvent is selected from tetrahydrofuran, or a mixture of tetrahydrofuran and any one or two or more solvents selected from methanol, ethanol, propanol, isopropanol, toluene, xylene, chlorobenzene, acetonitrile, 2-methyltetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, ethyl acetate, isopropyl ether, methyl tert-butyl ether, hexane, cyclohexane, and n-heptane.

Citation Information

Patent Citations

  • LFA-1 inhibitor and polymorph thereof

    CN104797574A

  • Method for synthesis of eliglustat and intermediate compounds thereof

    CN110461826A

  • Process for preparing and purifying the lfa-1 antagonist lifitegrast

    CN110944996A

  • Lifitegrast impurity and preparation method thereof

    CN111100118A